News & Updates
Filter by Specialty:
Self-reported adverse reactions less likely after inactivated CZ02 vs mRNA-based BNT162b2
A prospective cohort study by the University of Hong Kong comparing the reactogenicity of coronavirus disease 2019 (COVID-19) vaccines reports a lower risk of self-reported adverse reactions following vaccination with inactivated CZ02 compared with mRNA-based BNT162b2.
Self-reported adverse reactions less likely after inactivated CZ02 vs mRNA-based BNT162b2
23 Feb 2022
BNT162b2 and CZ02 neutralizing antibody titres lower against Omicron vs earlier variants
A study by the University of Hong Kong (HKU) has found that immune sera from mRNA-based BNT162b2 and inactivated CZ02 vaccine recipients have substantially reduced neutralizing antibody titres against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
BNT162b2 and CZ02 neutralizing antibody titres lower against Omicron vs earlier variants
23 Feb 2022
Increased risk of herpes zoster hospitalization after COVID-19 vaccination
A self-controlled case series reported by researchers from the University of Hong Kong has identified an increased risk of herpes zoster–related hospitalization associated with mRNA-based BNT162b2 and inactivated CZ02 vaccination against coronavirus disease 2019 (COVID-19).
Increased risk of herpes zoster hospitalization after COVID-19 vaccination
23 Feb 2022
Hypertension in pregnancy: Labetalol extends benefits for pregnancy outcomes
Common blood pressure (BP)-lowering medications in pregnancy cut the risk of severe hypertension, but labetalol has the added advantage of reducing the risks of proteinuria or pre-eclampsia and perinatal death, according to the results of a network meta-analysis.
Hypertension in pregnancy: Labetalol extends benefits for pregnancy outcomes
22 Feb 2022
First-line biologic therapy persists longer than later agents in ankylosing spondylitis
Biologic disease-modifying antirheumatic drug (bDMARD) therapy is effective in reducing ankylosing spondylitis (AS) disease activity, reports a study, noting how treatment has persisted for up to 8 years among patients remaining on their first bDMARD, which is longer than on subsequent agents.
First-line biologic therapy persists longer than later agents in ankylosing spondylitis
22 Feb 2022
NOACs preferable over warfarin in AF patients with bioprosthetic valves
Use of nonvitamin K oral anticoagulants (NOACs) results in a reduced incidence of thromboembolic events and major bleeding relative to warfarin in patients with atrial fibrillation (AF) and bioprosthetic valves or valve repair, suggests a study.
NOACs preferable over warfarin in AF patients with bioprosthetic valves
22 Feb 2022
Proinflammatory diet ups risk of nonalcoholic fatty liver disease
A dietary pattern with high inflammatory potential contributes to an increased risk of nonalcoholic fatty liver disease (NAFLD), a recent study has shown.